Markéta Černovská

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim et al. · The Lancet Oncology · 2018 · 576 citations · Full text

Medicine, Oncology, Pharmacology +8

Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer

Martin Svatoň, Milada Zemanová, Petra Zemanová et al. · Anticancer Research · 2020 · 86 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +13

Care of patients with non-small-cell lung cancer stage III – the Central European real-world experience

Milada Zemanová, Robert Pirker, Luboš Petruželka et al. · Radiology and Oncology · 2020 · 13 citations · Full text

Medicine, Nuclear Medicine, Oncology +14

Autologous dendritic cell-based immunotherapy (DCVAC/LuCa) and carboplatin/paclitaxel in advanced non-small cell lung cancer: A randomized, open-label, phase I/II trial

Milada Zemanová, Markéta Černovská, Libor Havel et al. · Cancer Treatment and Research Communications · 2021 · 13 citations · Full text

Medicine, Immunology, Oncology +15

VATS lobectomy, history, indication, contraindication and general techniques

Vladislav Hytych, P. Horažďovský, Radek Pohnán et al. · Bratislavské lekárske listy/Bratislava medical journal · 2015 · 10 citations · Full text

Medicine, Surgery, Cardiothoracic Surgery +14